Mabthera SC approved for PBS reimbursement in Australia

A new time-saving subcutaneous formulation of MabThera has been approved by the PBS in Australia for the treatment of common forms of non-Hodgkin Lymphoma.

MabThera is a therapeutic monoclonal antibody
that binds to a particular protein – the CD20 antigen – on the surface of
normal and malignant B-cells. It then recruits the body’s natural defences to
attack and kill the marked B-cells. Stem cells (B-cell progenitors) in bone
marrow lack the CD20 antigen, allowing healthy B-cells to regenerate after
treatment and return to normal levels within several months.

MabThera is used to treat non-Hodgkin’s lymphoma
with chemotherapy or it can also be used on its own. To date many lymphoma
patients may have received MabThera via intravenous infusion over a number of
hours. However the approval of MabThera SC (subcutaneous injection) can mean a fast
five minute administration time that is significantly improving the treatment
experience for patients w
hilst saving valuable time for health systems 

The listing on the Australian Pharmaceutical Benefits Scheme from the 1st
of April will be for:

  • Relapsed or refractory Stage III or
    IV CD20 positive follicular B-cell non-Hodgkin's lymphoma

  • Relapsed or refractory low-grade
    B-cell non-Hodgkin's lymphoma

  • Relapsed or refractory follicular
    B-cell non-Hodgkin's lymphoma

  • Stage III or IV CD20 positive
    follicular B-cell non-Hodgkin's lymphoma

  • Previously untreated CD20 positive
    diffuse large B-cell non-Hodgkin's lymphoma

    Patients should
    ask their treating doctors if they would like more information on this
    medicine.

 

 

Share This

Newsletter Sign Up

Contact Lymphoma Australia Today!